According to Anke Biotech, recently, the company's shareholding company Hefei Afana Biotechnology Co., Ltd. announced that it has completed the first round of A round of financing. The total volume of Series A financing was 50 million US dollars. The first round was led by Guozhong Capital, co-led by Life and Health Company under the Hefei Industrial Investment Group, and Anhui Ceyuan Industrial Investment Co., Ltd.; additional investments were made by venture capital guidance fund companies under the Hefei Industrial Investment Group, followed by Nanjing Hongjing, Shenzhen Jiurong, and Shanghai Qinli. This round of financing will mainly be used to accelerate the efficient promotion of core pipelines such as Afana BioPharm-T and tumor vaccines, continue to iterate the TALENT technology platform, further strengthen the company's comprehensive capabilities in CMC, registered development and industrialization, and accelerate innovative therapies with global competitiveness into clinical and subsequent development stages.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.